Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

Ana Luísa Caires de Souza; Francisco de Assis Acurcio; Augusto Afonso  Guerra Júnior; Renata Cristina Rezende Macedo do Nascimento; Brian Godman; Leonardo Maurício Diniz

doi:10.1007/s40258-014-0113-x

Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior, Renata Cristina Rezende Macedo do Nascimento, Brian Godman, Leonardo Maurício Diniz

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

69 Downloads (Pure)

Abstract

Dear Editor,

We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients.

However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.

Original language	English
Pages (from-to)	561-563
Number of pages	3
Journal	Applied Health Economics and Health Policy
Volume	12
Issue number	5
Early online date	14 Aug 2014
DOIs	https://doi.org/10.1007/s40258-014-0113-x
Publication status	Published - 1 Oct 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

insulin glargine
Brazil
insulin analogues

Access to Document

10.1007/s40258-014-0113-x

Godman-etal-AHEHP-2014-Authors-reply-to-Dr-MalerbiAccepted author manuscript, 295 KB

Cite this

@article{e9799b6c8ede41a49d4f87a73ab9b445,

title = "Authors{\textquoteright} reply to Dr. Malerbi: {"}Insulin glargine in a Brazilian state: should the government disinvest?{"}",

abstract = "Dear Editor, We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients. However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”. ",

keywords = "insulin glargine, Brazil, insulin analogues",

author = "\{de Souza\}, \{Ana Lu{\'i}sa Caires\} and Acurcio, \{Francisco de Assis\} and \{Guerra J{\'u}nior\}, \{Augusto Afonso\} and \{do Nascimento\}, \{Renata Cristina Rezende Macedo\} and Brian Godman and Diniz, \{Leonardo Maur{\'i}cio\}",

year = "2014",

month = oct,

day = "1",

doi = "10.1007/s40258-014-0113-x",

language = "English",

volume = "12",

pages = "561--563",

journal = "Applied Health Economics and Health Policy",

issn = "1175-5652",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

AU - de Souza, Ana Luísa Caires

AU - Acurcio, Francisco de Assis

AU - Guerra Júnior, Augusto Afonso

AU - do Nascimento, Renata Cristina Rezende Macedo

AU - Godman, Brian

AU - Diniz, Leonardo Maurício

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Dear Editor, We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients. However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.

AB - Dear Editor, We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients. However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.

KW - insulin glargine

KW - Brazil

KW - insulin analogues

U2 - 10.1007/s40258-014-0113-x

DO - 10.1007/s40258-014-0113-x

M3 - Article

SN - 1175-5652

VL - 12

SP - 561

EP - 563

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

IS - 5

ER -

Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this